Skip to main content
Top
Published in: Rheumatology International 2/2018

01-02-2018 | Imaging

Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review

Authors: Isidora T. Grozdic Milojevic, Bogomir Milojevic, Dragana P. Sobic-Saranovic, Vera M. Artiko

Published in: Rheumatology International | Issue 2/2018

Login to get access

Abstract

The aim of this article was to critically assess the usefulness of hybrid molecular imaging (FDG PET/CT and FDG PET/MR) procedures in the evaluation of inflammatory activity in retroperitoneal fibrosis (RPF). A systematic review of the literature was performed using PubMed without timeline restriction and using the following keywords: retroperitoneal fibrosis, disease activity, diagnostic techniques, PET/CT, PET/MR. We evaluated full text articles written in the English language. Case reports, review articles or editorials and articles not in the field of interest of this review were excluded. Nine articles comprising a total of 186 patients met the inclusion criteria and were included and described in this systematic review. The new hybrid molecular imaging methods give promising results in the evaluation of the activity of the disease, quantification and prediction of therapeutic response and in tailoring medical therapy in RPF. FDG PET/CT can be a valuable tool in detecting disease activity, particularly in asymptomatic patients with RPF with acute phase reactant increase. Hybrid imaging can predict therapy response outcome and the best time for stent removal. Although PET/MR has potential advantage in small lesions and has reduced radiation exposure in comparison to PET/CT, PET quantification parameters have potentially higher diagnostic value over MR parameters in the evaluation of RPF. Acute phase reactants alone may not be reliable for the management and follow-up assessment of the disease. Hybrid imaging in RFP could be more comfortable, more accurate, with less radiation burden than different separate imaging studies acquired at different points in time.
Literature
1.
go back to reference VaglioA Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet 367(9506):241–251CrossRef VaglioA Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet 367(9506):241–251CrossRef
2.
go back to reference Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res 23(3):339–353CrossRef Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res 23(3):339–353CrossRef
4.
go back to reference Otomi Y, Otsuka H, Terazawa K, Nose H, Kubo M, Yoneda K, Kitsukawa K, Harada M (2013) (18)F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls. J Med Invest 60(1–2):15–20CrossRefPubMed Otomi Y, Otsuka H, Terazawa K, Nose H, Kubo M, Yoneda K, Kitsukawa K, Harada M (2013) (18)F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls. J Med Invest 60(1–2):15–20CrossRefPubMed
5.
go back to reference Yilmaz S, Tanb YZ, Ozhan M, Halac M, Asa S, Sönmezoglu K (2012) FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol 31(6):338–339PubMed Yilmaz S, Tanb YZ, Ozhan M, Halac M, Asa S, Sönmezoglu K (2012) FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol 31(6):338–339PubMed
7.
go back to reference Mehta A, Blodgett MT (2011) Retroperitoneal Fibrosis as a cause of positive FDG PET/CT. J Radiol Case Reports 5(7):35–41CrossRef Mehta A, Blodgett MT (2011) Retroperitoneal Fibrosis as a cause of positive FDG PET/CT. J Radiol Case Reports 5(7):35–41CrossRef
8.
go back to reference Van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625CrossRefPubMed Van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625CrossRefPubMed
9.
go back to reference Monev S (2002) Idiopathic retroperitoneal fibrosis:prompt diagnosis preserves organ function. Cleve Clin J Med 69:160–166CrossRefPubMed Monev S (2002) Idiopathic retroperitoneal fibrosis:prompt diagnosis preserves organ function. Cleve Clin J Med 69:160–166CrossRefPubMed
10.
go back to reference Bertagna F, Treglia G, Leccisotti L (2012) [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol 30:415–421CrossRefPubMed Bertagna F, Treglia G, Leccisotti L (2012) [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol 30:415–421CrossRefPubMed
11.
go back to reference Kottra JJ, Dunnick NR (1996) Retroperitoneal fibrosis. Radiol Clin North Am 43:1259–1275 Kottra JJ, Dunnick NR (1996) Retroperitoneal fibrosis. Radiol Clin North Am 43:1259–1275
12.
go back to reference Talati SJ, Abghari R, Kochkodan JJ, Helmer SR (1995) Use of Ga-67 imaging in diagnosis and follow-up after steroid treatment of retroperitoneal fibrosis. Clin Nucl Med 20:995–997CrossRefPubMed Talati SJ, Abghari R, Kochkodan JJ, Helmer SR (1995) Use of Ga-67 imaging in diagnosis and follow-up after steroid treatment of retroperitoneal fibrosis. Clin Nucl Med 20:995–997CrossRefPubMed
13.
go back to reference Treglia G, Mattoli MV, Bertagna F, Giubbini R, Giordano A (2013) Emerging role of Fluorine-18-fluorodeoxy glucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 33:549–555CrossRefPubMed Treglia G, Mattoli MV, Bertagna F, Giubbini R, Giordano A (2013) Emerging role of Fluorine-18-fluorodeoxy glucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 33:549–555CrossRefPubMed
14.
go back to reference Nakajo M, Jinnouchi S, Tanabe H, Tateno R, Nakajo M (2007) 18F-fluoro deoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr 31(4):539–543CrossRefPubMed Nakajo M, Jinnouchi S, Tanabe H, Tateno R, Nakajo M (2007) 18F-fluoro deoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr 31(4):539–543CrossRefPubMed
15.
go back to reference Piccoli GB, ConsiglioV Arena V, Pelosi E, Anastasios D, Ragni F, Fiori C, Cortese G, Deagostini MC, Porpiglia F, Scarpa RM (2010) Positron emission tomography as a tool for the‘tailored’management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transpl 25(8):2603–2610CrossRef Piccoli GB, ConsiglioV Arena V, Pelosi E, Anastasios D, Ragni F, Fiori C, Cortese G, Deagostini MC, Porpiglia F, Scarpa RM (2010) Positron emission tomography as a tool for the‘tailored’management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transpl 25(8):2603–2610CrossRef
16.
go back to reference Guignard R, Simukoniene M, Garibotto V, Ratib O (2012) 18F-FDG PET/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med 37(5):453–459CrossRefPubMed Guignard R, Simukoniene M, Garibotto V, Ratib O (2012) 18F-FDG PET/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med 37(5):453–459CrossRefPubMed
17.
go back to reference Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, Martinelli I, Messa P, Gerundini P (2012) The value of 18FFDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39:1635–1642CrossRefPubMed Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, Martinelli I, Messa P, Gerundini P (2012) The value of 18FFDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39:1635–1642CrossRefPubMed
18.
go back to reference Fofi C, Prosperi D, Pettorini L, Festuccia F, Pirisino R, Lanni V, Scopinaro F, Punzo G, Menè P (2016) Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET/CT and biochemical parameters in patients with renal involvement. Intern Emerg Med 11(6):809–816CrossRefPubMed Fofi C, Prosperi D, Pettorini L, Festuccia F, Pirisino R, Lanni V, Scopinaro F, Punzo G, Menè P (2016) Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET/CT and biochemical parameters in patients with renal involvement. Intern Emerg Med 11(6):809–816CrossRefPubMed
19.
go back to reference Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 43(9):1646–1652CrossRefPubMed Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 43(9):1646–1652CrossRefPubMed
20.
go back to reference Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T (2016) [18F]-fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. doi:10.1016/j.eururo.2016.10.046 PubMed Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T (2016) [18F]-fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. doi:10.​1016/​j.​eururo.​2016.​10.​046 PubMed
21.
go back to reference Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease activity and vascular involvement in retroperitoneal fibrosis: first experience with fully integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging compared to clinical and laboratory parameters. Clin Exp Rheumatol 35 Suppl 103(1):146–154PubMed Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease activity and vascular involvement in retroperitoneal fibrosis: first experience with fully integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging compared to clinical and laboratory parameters. Clin Exp Rheumatol 35 Suppl 103(1):146–154PubMed
22.
go back to reference Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, Beyer T (2005) Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 46(4):608–613PubMed Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, Beyer T (2005) Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 46(4):608–613PubMed
23.
go back to reference Tonkopi E, Ross AA, MacDonald A (2013) Journal club: CT dose optimization for whole-body PET/CT examinations. AJR Am J Roentgenol 201(2):257–263CrossRefPubMed Tonkopi E, Ross AA, MacDonald A (2013) Journal club: CT dose optimization for whole-body PET/CT examinations. AJR Am J Roentgenol 201(2):257–263CrossRefPubMed
24.
go back to reference Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE (1999) Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 33(5):829–839CrossRefPubMed Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE (1999) Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 33(5):829–839CrossRefPubMed
Metadata
Title
Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review
Authors
Isidora T. Grozdic Milojevic
Bogomir Milojevic
Dragana P. Sobic-Saranovic
Vera M. Artiko
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2018
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3798-y

Other articles of this Issue 2/2018

Rheumatology International 2/2018 Go to the issue

Cohort Studies on Comorbidities

Addressing comorbidities in psoriatic disease